19 results on '"Ileana Elias"'
Search Results
2. Supplementary Figure legend from Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
- Author
-
Razelle Kurzrock, Neil Desai, Ileana Elias, Shaoyi Li, Thorunn Helgason, Stacy Moulder, Jennifer Wheler, Siqing Fu, Aung Naing, Huiqin Chen, Argun Akcakanat, David Hong, Gerald Falchook, Sant Chawla, Funda Meric-Bernstam, and Ana M. Gonzalez-Angulo
- Abstract
Supplementary Figure legend
- Published
- 2023
3. Data from Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
- Author
-
Razelle Kurzrock, Neil Desai, Ileana Elias, Shaoyi Li, Thorunn Helgason, Stacy Moulder, Jennifer Wheler, Siqing Fu, Aung Naing, Huiqin Chen, Argun Akcakanat, David Hong, Gerald Falchook, Sant Chawla, Funda Meric-Bernstam, and Ana M. Gonzalez-Angulo
- Abstract
Purpose: This dose-finding phase I study investigated the maximum-tolerated dose (MTD) and safety of weekly nanoparticle albumin-bound rapamycin (nab-rapamycin) in patients with untreatable advanced nonhematologic malignancies.Experimental Design:nab-Rapamycin was administered weekly for 3 weeks followed by 1 week of rest, with a starting dose of 45 mg/m2. Additional doses were 56.25, 100, 150, and 125 mg/m2.Results: Of 27 enrolled patients, 26 were treated. Two dose-limiting toxicities (DLT) occurred at 150 mg/m2 [grade 3 aspartate aminotransferase (AST) elevation and grade 4 thrombocytopenia], and two DLTs occurred at 125 mg/m2 (grade 3 suicidal ideation and grade 3 hypophosphatemia). Thus, the MTD was declared at 100 mg/m2. Most treatment-related adverse events (TRAE) were grade 1/2, including thrombocytopenia (58%), hypokalemia (23%), mucositis (38%), fatigue (27%), rash (23%), diarrhea (23%), nausea (19%), anemia (19%), hypophosphatemia (19%), neutropenia (15%), and hypertriglyceridemia (15%). Only one grade 3 nonhematologic TRAE (dyspnea) and one grade 3 hematologic event (anemia) occurred at the MTD. One patient with kidney cancer had a partial response and 2 patients remained on study for 365 days (patient with mesothelioma) and 238 days (patient with neuroendocrine tumor). The peak concentration (Cmax) and area under the concentration–time curve (AUC) of rapamycin increased with dose between 45 and 150 mg/m2, except for a relatively low AUC at 125 mg/m2. nab-Rapamycin significantly inhibited mTOR targets S6K and 4EBP1.Conclusions: The clinical dose of single-agent nab-rapamycin was established at 100 mg/m2 weekly (3 of 4 weeks) given intravenously, which was well tolerated with preliminary evidence of response and stable disease, and produced a fairly dose-proportional pharmacokinetic profile in patients with unresectable advanced nonhematologic malignancies. Clin Cancer Res; 19(19); 5474–84. ©2013 AACR.
- Published
- 2023
4. Supplementary Fig 2 from Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
- Author
-
Razelle Kurzrock, Neil Desai, Ileana Elias, Shaoyi Li, Thorunn Helgason, Stacy Moulder, Jennifer Wheler, Siqing Fu, Aung Naing, Huiqin Chen, Argun Akcakanat, David Hong, Gerald Falchook, Sant Chawla, Funda Meric-Bernstam, and Ana M. Gonzalez-Angulo
- Abstract
A) Association of PBMC 4EBP1 T70 levels with serum rapamycin concentrations; B) Association of PBMC S6K T389 levels with serum rapamycin concentrations
- Published
- 2023
5. Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data
- Author
-
Warren P. Mason, Santosh Kesari, Mohit Trikha, Nancy Levin, Benjamin Winograd, Daniela A. Bota, Steven D. Reich, Ileana Elias, Annick Desjardins, and Rajiv Magge
- Subjects
Oncology ,clinical trials ,medicine.medical_specialty ,Bevacizumab ,business.industry ,Recurrent glioblastoma ,Clinical Investigations ,glioblastoma ,Clinical trial ,Phase i ii ,Pooled analysis ,Internal medicine ,medicine ,Dose escalation ,AcademicSubjects/MED00300 ,AcademicSubjects/MED00310 ,In patient ,marizomib ,business ,Complete response ,medicine.drug - Abstract
Background This phase I/II trial in patients with recurrent glioblastoma (GBM) evaluates the safety and preliminary efficacy of marizomib, an irreversible pan-proteasome inhibitor that crosses the blood–brain barrier. Methods Part A assessed the safety and efficacy of marizomib monotherapy. In Part B, escalating doses of marizomib (0.5–0.8 mg/m2) in combination with bevacizumab were evaluated. Part C explored intra-patient dose escalation of marizomib (0.8–1.0 mg/m2) for the combination. Results In Part A, 30 patients received marizomib monotherapy. The most common AEs were fatigue (66.7%), headache (46.7%), hallucination (43.3%), and insomnia (43.3%). One patient (3.3%) achieved a partial response. In Part B, the recommended phase II dose of marizomib was 0.8 mg/m2 when combined with bevacizumab 10 mg/kg. In Part C, dose escalation to 1.0 mg/m2 was not tolerated. Pooled analysis of 67 patients treated with marizomib ≤0.8 mg/m2 and bevacizumab showed a nonoverlapping safety profile consistent with the known safety profile of each agent: the most common grade ≥3 AEs were hypertension (16.4%), confusion (13.4%), headache (10.4%), and fatigue (10.4%). The overall response rate was 34.3%, including 2 patients with complete response. Six-month progression-free survival was 29.8%; median overall survival was 9.1 months. Conclusions The safety profile of marizomib as monotherapy and in combination with bevacizumab was consistent with previous observations that marizomib crosses the blood–brain barrier. Preliminary efficacy did not demonstrate a meaningful benefit of the addition of marizomib to bevacizumab for the treatment of recurrent GBM.
- Published
- 2021
6. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer
- Author
-
Ileana Elias, Pooja Hingorani, Birgit Geoerger, Nianhang Chen, Pascal Chastagner, Gianni Bisogno, Nicolas U. Gerber, Stefano Ferrara, Gilles Vassal, Ruta Slepetis, Pablo Berlanga, Julia C. Chisholm, Michela Casanova, Loredana Amoroso, Lucas Moreno, Julia L. Glade Bender, Sylvain Baruchel, Mathew Simcock, Christophe Bergeron, Soledad Gallego Melcon, Isabelle Aerts, Yvan Le Bruchec, Franca Fagioli, University of Zurich, and Moreno, Lucas
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Time Factors ,Gastroenterology ,nab-paclitaxel ,Neuroblastoma ,0302 clinical medicine ,Neoplasms ,Rhabdomyosarcoma ,1306 Cancer Research ,Drug Dosage Calculations ,Child ,Leukopenia ,Not Otherwise Specified ,Age Factors ,Metastatic breast cancer ,Europe ,Treatment Outcome ,Oncology ,Tolerability ,Paediatric ,Child, Preschool ,030220 oncology & carcinogenesis ,2730 Oncology ,Female ,Sarcoma ,medicine.symptom ,Canada ,medicine.medical_specialty ,Adolescent ,Maximum Tolerated Dose ,Paclitaxel ,610 Medicine & health ,Ewing sarcoma ,Solid tumour ,Neutropenia ,Drug Administration Schedule ,03 medical and health sciences ,Refractory ,Albumins ,Internal medicine ,medicine ,Humans ,business.industry ,medicine.disease ,Antineoplastic Agents, Phytogenic ,United States ,030104 developmental biology ,10036 Medical Clinic ,business ,Ewing sarcoma, Neuroblastoma, Paediatric, Rhabdomyosarcoma, Solid tumour, nab-paclitaxel - Abstract
Background nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in paediatric patients with recurrent/refractory solid tumours treated with nab-paclitaxel are reported. Patients and methods Patients with recurrent/refractory extracranial solid tumours received nab-paclitaxel on days 1, 8 and 15 every 4 weeks at 120, 150, 180, 210, 240, or 270 mg/m2 (rolling-6 dose-escalation) to establish the maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Results Sixty-four patients were treated. Dose-limiting toxicities were grade 3 dizziness at 120 mg/m2 and grade 4 neutropenia >7 days at 270 mg/m2. The most frequent grade 3/4 adverse events were haematologic, including neutropenia (36%), leukopenia (36%) and lymphopenia (25%). Although the MTD was not reached, 270 mg/m2 was declared non-tolerable due to grade 3/4 toxicities during cycles 1–2 (neutropenia, n = 5/7; skin toxicity, n = 2/7; peripheral neuropathy, n = 1/7). Of 58 efficacy-evaluable patients, complete response occurred in one patient (2%; Ewing sarcoma) and partial responses in four patients (7%; rhabdomyosarcoma, Ewing sarcoma, renal tumour with pulmonary metastases [high-grade, malignant] and sarcoma not otherwise specified); all responses occurred at ≥210 mg/m2. Thirteen patients (22%) had stable disease (5 lasting ≥16 weeks) per RECIST. Conclusions nab-Paclitaxel 240 mg/m2 qw3/4 (nearly double the adult recommended monotherapy dose for this schedule in metastatic breast cancer) was selected as the RP2D based on the tolerability profile, pharmacokinetics and antitumour activity. Phase II is currently enrolling patients with recurrent/refractory neuroblastoma, rhabdomyosarcoma and Ewing sarcoma. ClinicalTrials.gov NCT01962103. EudraCT 2013-000144-26.
- Published
- 2018
7. RBTT-08. EORTC 1709/CCTG CE.8: A PHASE III TRIAL OF MARIZOMIB IN COMBINATION WITH STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY VERSUS STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
- Author
-
Patrick Roth, Jaap Reijneveld, Thierry Gorlia, Frederic Dhermain, Maureen Vanlancker, Beatrice Fournier, Sarah Nuyens, Chris O’Callaghan, Emilie Le Rhun, Ileana Elias, Martin van den Bent, Warren Mason, Benjamin Winograd, and Michael Weller
- Subjects
Cancer Research ,Abstracts ,Oncology ,Neurology (clinical) - Abstract
BACKGROUND: The standard of care for patients with newly diagnosed glioblastoma includes maximum safe surgery, involved-field radiotherapy (RT), and concomitant and up to six cycles of maintenance temozolomide (TMZ) chemotherapy (TMZ/RT→TMZ). However, the prognosis remains poor and there is a high unmet need to provide new drugs to patients with glioblastoma. Marizomib is a novel, brain-penetrant irreversible pan-proteasome inhibitor that has been successfully assessed in phase I studies in patients with newly diagnosed as well as recurrent glioblastoma. METHODS: EORTC 1709/CCTG CE.8 is a multicenter, randomized, controlled, open label phase III superiority trial. To be eligible, patients need to have histologically confirmed newly diagnosed glioblastoma. A total of 750 patients will be enrolled and randomized 1:1. Stratification factors include institution, age, Karnofsky performance status and extent of surgery. The primary objective of this study is to compare overall survival in patients receiving marizomib in addition to standard treatment (TMZ/RT→TMZ) with patients receiving standard treatment only. The testing strategy is defined to assess this objective in both the intent-to-treat population and the subgroup of patients with tumors harboring an unmethylated O(6)-methylguanine-DNA methyltransferase (MGMT) promoter. Secondary endpoints include progression-free survival, safety, neurocognitive function and quality of life. An accompanying translational research program has been set up. The study will be opened at 50 EORTC sites in Europe and done as an intergroup collaboration with the Canadian Cancer Trials Group (CCTG) with 25 sites in Canada and additional sites in the US. Patient enrolment is planned to start in June 2018 and an update on the enrolment status will be provided at the SNO conference. ClinicalTrials.gov Identifier: NCT03345095
- Published
- 2018
8. Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM)
- Author
-
Roger Stupp, Benjamin Winograd, Daniela A. Bota, Patrick Roth, David Piccioni, Dawit Aregawi, Marie-Laure Casadebaig, Nancy Levin, Steven D. Reich, Ileana Elias, Annick Desjardins, Warren P. Mason, and Santosh Kesari
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Temozolomide ,business.industry ,medicine.medical_treatment ,Newly diagnosed ,Extended phase ,medicine.disease ,Radiation therapy ,03 medical and health sciences ,0302 clinical medicine ,Open label study ,030220 oncology & carcinogenesis ,Internal medicine ,Glioma ,medicine ,business ,030215 immunology ,Therapeutic strategy ,medicine.drug ,Glioblastoma - Abstract
2021 Background: Proteasome inhibition sensitizes glioma cells to TMZ and RT, providing a novel therapeutic strategy for GBM. MRZ, an irreversible, brain-penetrant, pan-proteasome inhibitor with anti-glioma activity was combined with standard TMZ/RT → TMZ in newly diagnosed GBM (NCT02903069), to determine the recommended dose (RD). The primary endpoint of this expanded phase 1 trial was toxicity, with secondary endpoint of OS. Methods: Patients were enrolled in separate cohorts (TMZ/RT+MRZ→TMZ+MRZ, N=15; TMZ/RT→TMZ+MRZ, N=18) in dose-escalation (3+3 design), followed by dose-expansion (N=20) with TMZ/RT+MRZ at RD → TMZ+MRZ at RD. A separate cohort received TMZ/RT→TMZ+MRZ at RD with Tumor Treating Fields (Optune, N=13). MRZ was infused IV (10 min at 0.55, 0.7, 0.8, and 1.0 mg/m2) on Days 1, 8, 15, 29, 36 (42-day TMZ/RT+MRZ cycle) and Days 1, 8, 15 (28-day TMZ+MRZ cycle). Results: 66 patients treated; median age 58 years, 68% male, 50% receiving corticosteroid at baseline, 52% unmethylated MGMT. Dose-limiting toxicities (DLTs) in dose-escalation cohorts: 1 (fatigue) at 0.7 mg/m2 MRZ, 5 (ataxia/diarrhea; ataxia/confusion; myocardial infarction, delirium/ataxia; ataxia/fatigue) in 1.0 mg/m2 cohorts. MRZ demonstrated a steep dose-response with treatment-emergent adverse events (TEAEs)/DLTs predominately CNS AEs (Grade ≥3 TEAEs in 12 of 12 patients at 1.0 mg/m2 vs 22 of 41 patients at ≤0.8 mg/m2); the RD for MRZ was determined to be 0.8 mg/m2. Most common TEAEs (all grades): fatigue, nausea (both 70%), hallucination (54%), vomiting (53%), headache (47%), confusional state (33%), ataxia, constipation, muscular weakness (all 29%). Conclusions: CNS TEAEs were short-lasting, reversible and ameliorated by early dose reductions (29% patients dose-reduced), allowing patients to remain on treatment. For patients receiving MRZ with TMZ/RT→TMZ (N=35), the median OS was 14.8 months (17 deaths, median follow-up 14.3 months), and 7 patients remain active (Cycles 11-23). The MRZ RD + TMZ/Optune combination was tolerated, with 4 of 13 patients treated on this arm remaining active. An international Phase 3 trial (EORTC 1709-BTG/CCTG CE.8, NCT03345095) is ongoing. Clinical trial information: NCT02903069.
- Published
- 2019
9. ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS
- Author
-
Warren P. Mason, Roger Stupp, Patrick Roth, David Piccioni, Benjamin Winograd, Ileana Elias, Annick Desjardins, Steven D. Reich, Mingyu Li, Dawit Aregawi, Santosh Kesari, Daniela A. Bota, and Nancy Levin
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Multicatalytic endopeptidase complex ,Temozolomide ,business.industry ,medicine.medical_treatment ,Oncology and Carcinogenesis ,Neurosciences ,Newly diagnosed ,Who grade ,medicine.disease ,Radiation therapy ,Abstracts ,Open label study ,Glioma ,Internal medicine ,Medicine ,Oncology & Carcinogenesis ,Neurology (clinical) ,business ,Cancer ,medicine.drug ,Glioblastoma - Abstract
Proteasome inhibition sensitizes glioma cells to TMZ and RT, providing a novel therapeutic strategy for ndGBM. MRZ, an irreversible, brain-penetrant, pan-proteasome inhibitor with anti-glioma activity was combined with standard-of-care (SOC) concomitant TMZ/RT followed by adjuvant TMZ in ndGBM (NCT02903069), to determine the recommended dose (RD). Patients were enrolled in separate concomitant (TMZ/RT+MRZ, N=15) and adjuvant (TMZ+MRZ, N=18) cohorts in dose-escalation (3 + 3 design), followed by dose-expansion (N=20) at RD (0.8 mg/m2) in concomitant followed by adjuvant treatment. MRZ infused IV (10 min) at increasing dose levels (0.55, 0.7, 0.8, and 1.0 mg/m2): Concomitant days 1, 8, 15, 29, 36; Adjuvant days 1, 8, 15 (28-day cycle). RESULTS (as of 02May2018): Mean age 55 years, 68% male. Most common treatment-emergent adverse events (TEAEs, 20% patients, all grades): fatigue, nausea, vomiting, hallucination, ataxia, headache. Dose-limiting toxicities (DLTs): 1 (fatigue) at 0.7 mg/m2 adjuvant cohort, 3 (ataxia/diarrhea; ataxia/confusion; myocardial infarction) in concomitant and 2 (delirium/ataxia; ataxia/fatigue) in adjuvant cohorts at 1.0 mg/m2. Grade 3 TEAEs in 11 of 12 patients at 1.0 mg/m2 including one Grade 4 and one Grade 5 TEAE; at 0.8 mg/m2 MRZ, Grade 3 TEAEs in 9 of 21 patients. MRZ demonstrated a steep dose-response with TEAEs/DLTs predominately CNS AEs (ataxia, hallucinations) which were dose-related, short-lasting, reversible and ameliorated by early dose reductions, allowing patients to remain on treatment. Currently 8 dose-escalation patients remain active in Cycle 10–23. Median OS for dose-expansion not yet estimated; 7 patients remain active, 1 death, median follow-up 4.1 months. MRZ at the RD with adjuvant TMZ+Tumor Treating Fields (Optune) is currently enrolling. An international Phase 3 trial (EORTC #1709-BTG, NCT03345095) has been launched in 2018 to assess the overall survival benefit of MRZ added to SOC in ndGBM.
- Published
- 2018
10. Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial
- Author
-
Ana M. Gonzalez-Angulo, Siqing Fu, David S. Hong, Sant Chawla, Shaoyi Li, Argun Akcakanat, Aung Naing, Funda Meric-Bernstam, Razelle Kurzrock, Ileana Elias, Huiqin Chen, Stacy L. Moulder, Neil P. Desai, Jennifer J. Wheler, Gerald Steven Falchook, and Thorunn Helgason
- Subjects
Cancer Research ,medicine.medical_specialty ,Anemia ,business.industry ,Nausea ,Neutropenia ,medicine.disease ,Gastroenterology ,Rash ,Hypokalemia ,Surgery ,Oncology ,Pharmacokinetics ,Internal medicine ,medicine ,Mucositis ,medicine.symptom ,business ,Hypophosphatemia - Abstract
Purpose: This dose-finding phase I study investigated the maximum-tolerated dose (MTD) and safety of weekly nanoparticle albumin-bound rapamycin (nab-rapamycin) in patients with untreatable advanced nonhematologic malignancies. Experimental Design: nab-Rapamycin was administered weekly for 3 weeks followed by 1 week of rest, with a starting dose of 45 mg/m2. Additional doses were 56.25, 100, 150, and 125 mg/m2. Results: Of 27 enrolled patients, 26 were treated. Two dose-limiting toxicities (DLT) occurred at 150 mg/m2 [grade 3 aspartate aminotransferase (AST) elevation and grade 4 thrombocytopenia], and two DLTs occurred at 125 mg/m2 (grade 3 suicidal ideation and grade 3 hypophosphatemia). Thus, the MTD was declared at 100 mg/m2. Most treatment-related adverse events (TRAE) were grade 1/2, including thrombocytopenia (58%), hypokalemia (23%), mucositis (38%), fatigue (27%), rash (23%), diarrhea (23%), nausea (19%), anemia (19%), hypophosphatemia (19%), neutropenia (15%), and hypertriglyceridemia (15%). Only one grade 3 nonhematologic TRAE (dyspnea) and one grade 3 hematologic event (anemia) occurred at the MTD. One patient with kidney cancer had a partial response and 2 patients remained on study for 365 days (patient with mesothelioma) and 238 days (patient with neuroendocrine tumor). The peak concentration (Cmax) and area under the concentration–time curve (AUC) of rapamycin increased with dose between 45 and 150 mg/m2, except for a relatively low AUC at 125 mg/m2. nab-Rapamycin significantly inhibited mTOR targets S6K and 4EBP1. Conclusions: The clinical dose of single-agent nab-rapamycin was established at 100 mg/m2 weekly (3 of 4 weeks) given intravenously, which was well tolerated with preliminary evidence of response and stable disease, and produced a fairly dose-proportional pharmacokinetic profile in patients with unresectable advanced nonhematologic malignancies. Clin Cancer Res; 19(19); 5474–84. ©2013 AACR.
- Published
- 2013
11. Melanoma Clinics and Treatment
- Author
-
M. Del Vecchio, Alessandro Testori, Michael P. Brown, Mingyu Li, Richard F. Kefford, Carmen Loquai, Ileana Elias, Evan M. Hersh, Markus F. Renschler, J.-J. Grob, Caroline Robert, and Axel Hauschild
- Subjects
Gerontology ,Metastatic melanoma ,business.industry ,Dacarbazine ,Mutation (genetic algorithm) ,medicine ,Cancer research ,Dermatology ,business ,Chemotherapy naive ,Nab-paclitaxel ,medicine.drug - Published
- 2013
12. A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results
- Author
-
Ileana Elias, Dawit Aregawi, Annick Desjardins, Nancy Levin, Steven D. Reich, Roger Stupp, Benjamin Winograd, Daniela A. Bota, Mingyu Li, Warren P. Mason, Santosh Kesari, Patrick Roth, and David Piccioni
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Temozolomide ,business.industry ,medicine.medical_treatment ,Newly diagnosed ,Who grade ,medicine.disease ,030218 nuclear medicine & medical imaging ,Radiation therapy ,03 medical and health sciences ,0302 clinical medicine ,Open label study ,030220 oncology & carcinogenesis ,Internal medicine ,Glioma ,Dose escalation ,medicine ,business ,medicine.drug ,Glioblastoma - Abstract
e14083Background: Proteasome inhibition sensitizes glioma cells to TMZ and RT, providing a novel therapeutic strategy for ndGBM. MRZ, an irreversible, brain-penetrant, pan-proteasome inhibitor with...
- Published
- 2018
13. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma
- Author
-
Sanjiv S. Agarwala, Carmen Loquai, J.-J. Grob, S. Ernst, Alessandro Testori, Mingyu Li, Caroline Robert, Axel Hauschild, Evan M. Hersh, M. Karnoub, Richard F. Kefford, Robert M. Conry, M. Del Vecchio, Ralf Gutzmer, Andrew Haydon, Jade Homsi, Kari Kendra, Markus F. Renschler, S. Bhatia, Carrie Baker Brachmann, A. Clawson, Ileana Elias, and Michael P. Brown
- Subjects
Adult ,Male ,medicine.medical_specialty ,Skin Neoplasms ,Paclitaxel ,Dacarbazine ,Gastroenterology ,Disease-Free Survival ,law.invention ,Young Adult ,Randomized controlled trial ,law ,Internal medicine ,Albumins ,medicine ,Clinical endpoint ,Humans ,Progression-free survival ,Antineoplastic Agents, Alkylating ,Melanoma ,Aged ,Aged, 80 and over ,business.industry ,Hazard ratio ,Hematology ,Original Articles ,Middle Aged ,medicine.disease ,Chemotherapy regimen ,Confidence interval ,Surgery ,Oncology ,Female ,business ,medicine.drug - Abstract
The efficacy and safety of nab-paclitaxel versus dacarbazine in patients with metastatic melanoma was evaluated in a phase III randomized, controlled trial.Chemotherapy-naïve patients with stage IV melanoma received nab-paclitaxel 150 mg/m(2) on days 1, 8, and 15 every 4 weeks or dacarbazine 1000 mg/m(2) every 3 weeks. The primary end point was progression-free survival (PFS) by independent radiologic review; the secondary end point was overall survival (OS).A total of 529 patients were randomized to nab-paclitaxel (n = 264) or dacarbazine (n = 265). Baseline characteristics were well balanced. The majority of patients were men (66%), had an Eastern Cooperative Oncology Group status of 0 (71%), and had M1c stage disease (65%). The median PFS (primary end point) was 4.8 months with nab-paclitaxel and 2.5 months with dacarbazine [hazard ratio (HR), 0.792; 95.1% confidence interval (CI) 0.631-0.992; P = 0.044]. The median OS was 12.6 months with nab-paclitaxel and 10.5 months with dacarbazine (HR, 0.897; 95.1% CI 0.738-1.089; P = 0.271). Independently assessed overall response rate was 15% versus 11% (P = 0.239), and disease control rate (DCR) was 39% versus 27% (P = 0.004) for nab-paclitaxel versus dacarbazine, respectively. The most common grade ≥3 treatment-related adverse events were neuropathy (nab-paclitaxel, 25% versus dacarbazine, 0%; P0.001), and neutropenia (nab-paclitaxel, 20% versus dacarbazine, 10%; P = 0.004). There was no correlation between secreted protein acidic and rich in cysteine (SPARC) status and PFS in either treatment arm.nab-Paclitaxel significantly improved PFS and DCR compared with dacarbazine, with a manageable safety profile.
- Published
- 2014
14. Phase 1/2 study of weekly nab-paclitaxel (nab-P) in pediatric patients (pts) with recurrent/refractory solid tumors (STs): Dose-finding and pharmacokinetics (PK)
- Author
-
Soledad Gallego Melcon, Gilles Vassal, Julia L. Glade Bender, Pooja Hingorani, Nicolas U. Gerber, Gianni Bisogno, Mathew Simcock, Ruta Slepetis, Lucas Moreno, Pablo Berlanga, Carla Manzitti, Isabelle Aerts, Sylvain Baruchel, Ileana Elias, Birgit Geoerger, Julia C. Chisholm, Pascal Chastagner, Michela Casanova, Franca Fagioli, and Christophe Bergeron
- Subjects
Cancer Research ,business.industry ,Neurotoxicity ,macromolecular substances ,Pharmacology ,medicine.disease ,carbohydrates (lipids) ,stomatognathic diseases ,03 medical and health sciences ,Dose finding ,chemistry.chemical_compound ,0302 clinical medicine ,Oncology ,Refractory ,Pharmacokinetics ,Paclitaxel ,chemistry ,030225 pediatrics ,030220 oncology & carcinogenesis ,otorhinolaryngologic diseases ,medicine ,bacteria ,business ,Nab-paclitaxel - Abstract
10551Background: Although solvent-based paclitaxel has demonstrated activity in adult pts with STs, solvents produce significant neurotoxicity in pediatric pts. nab-P is an albumin–bound paclitaxel...
- Published
- 2016
15. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100
- Author
-
Teresa Petrella, Thorsten U. Vogel, Ileana Elias, Shailendra Verma, Neill Iscoe, Igor Astsaturov, Susan Burdett-Radoux, Paul Hamilton, Neil L. Berinstein, and David Spaner
- Subjects
Adult ,Male ,Cancer Research ,Skin Neoplasms ,medicine.medical_treatment ,Injections, Subcutaneous ,Genetic Vectors ,chemical and pharmacologic phenomena ,Enzyme-Linked Immunosorbent Assay ,CD8-Positive T-Lymphocytes ,complex mixtures ,Cancer Vaccines ,Canarypox virus ,Antigen ,HLA-A2 Antigen ,medicine ,Tetanus Toxoid ,Humans ,Melanoma ,Aged ,Membrane Glycoproteins ,HLA-A Antigens ,Tetanus ,business.industry ,ELISPOT ,Viral Vaccine ,Toxoid ,Middle Aged ,medicine.disease ,Virology ,Neoplasm Proteins ,Vaccination ,CTL ,Oncology ,Lymphatic Metastasis ,Immunology ,Female ,business ,Adjuvant ,gp100 Melanoma Antigen - Abstract
BACKGROUND The route of administration and extent of helper T-cell activation are factors that are likely to be important for the development of effective cancer vaccines. In order to optimize CD8+ cytotoxic T-lymphocyte (CTL) responses, the immunologic effects of direct lymph node (LN) injections of canary pox virus (ALVAC) vectors (expressing the melanoma antigen, gp100) and immunogenic gp100 peptides, along with concomitant injections of the helper adjuvant, tetanus toxoid, were studied in high-risk HLA-A*0201+ patients. METHODS Forty-two patients were vaccinated using six different protocols. Twenty-three patients were ‘primed’ with ALVAC(2)-gp100m and ‘boosted’ with gp100 peptides, either subcutaneously or into an LN. Intranodal (IN) peptides, alone, were administered to six patients. Thirteen patients were given tetanus toxoid initially, and with each gp100 vaccination. Toxicity was recorded and immunologic responses were determined in 35 patients by enzyme-linked immunospot (ELISPOT) and gp100-tetramer binding assays and anti-ALVAC(2) enzyme-linked immunosorbent assays (ELISAs). RESULTS All vaccine protocols were tolerated well. Using stringent criteria for immunologic response, 8 of 18 patients responded to the viral vaccines, in striking contrast to peptides only (0 of 6 patients) or with help in trans from tetanus-reactive T-cells (1 of 11 patients). Changes in gp100-reactive CTL frequencies and ALVAC antibodies were greatest when viruses were injected directly into LNs. CONCLUSIONS IN injections of ALVAC(2)-gp100m viruses are feasible, safe, and may be a superior method of vaccination in humans. CTL responses to this vaccine were not enhanced by tetanus toxoid. Cancer 2006. © 2006 American Cancer Society.
- Published
- 2006
16. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines
- Author
-
Igor, Astsaturov, Teresa, Petrella, E Umit, Bagriacik, Mark, de Benedette, Robert, Uger, Gail, Lumber, Neil, Berinstein, Ileana, Elias, Neill, Iscoe, Caitlin, Hammond, Paul, Hamilton, and David E, Spaner
- Subjects
Adult ,Cytotoxicity, Immunologic ,Male ,Membrane Glycoproteins ,HLA-A Antigens ,T-Lymphocytes ,Vaccination ,Interferon-alpha ,Antineoplastic Agents ,Enzyme-Linked Immunosorbent Assay ,Interferon alpha-2 ,Middle Aged ,Cancer Vaccines ,Canarypox virus ,Recombinant Proteins ,Neoplasm Proteins ,Lymphatic Metastasis ,HLA-A2 Antigen ,Humans ,Melanocytes ,Female ,Melanoma ,Cell Division ,gp100 Melanoma Antigen - Abstract
The therapeutic effectiveness of cancer vaccines, composed of tumor antigens that are also self-antigens, may be limited by the normal mechanisms that preserve immunological tolerance. Consistent with this notion, we found that vaccination of melanoma patients with recombinant viral vaccines expressing gp100 (a melanoma antigen also expressed by normal melanocytes) produced only transient increases in noncytotoxic T cells specific for immunodominant gp100 epitopes. To improve the therapeutic effects of these vaccines, IFN-alpha2b (IFN-alpha) was administered to some high-risk patients.7 HLA-A*0201(+) patients were injected with high doses of IFN-alpha (20 MU/m(2) x 20 doses) at various times after completing the vaccination protocol. Clinical toxicity and responses were documented, and the effects on gp100-reactive T cells were measured by IFN-gamma enzyme-linked immunospot assays, tetramers of HLA-A*0201 and gp100 epitopes, and cellular cytotoxicity assays.In patients who had previously responded to vaccination, high doses of IFN-alpha recalled gp100-reactive T cells with the ability to kill gp100-expressing tumor targets in vitro. Concomitant with the reappearance of these cytotoxic T cells, tumor regression was observed in the two patients with clinically evident metastatic disease.The finding that high-dose IFN recalls previously activated tumor-reactive T cells with potent killing ability suggests a strategy to maintain antitumor responses initiated by cancer vaccines.
- Published
- 2003
17. Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor
- Author
-
Richard L, Leff, Ileana, Elias, Mirela, Ionescu, Agnes, Reiner, and A Robin, Poole
- Subjects
Cartilage, Articular ,Male ,Extracellular Matrix Proteins ,Biphenyl Compounds ,Administration, Oral ,Antineoplastic Agents ,Matrix Metalloproteinase Inhibitors ,Middle Aged ,Osteoarthritis, Knee ,Phenylbutyrates ,Treatment Outcome ,Synovial Fluid ,Humans ,Female ,Lectins, C-Type ,Proteoglycans ,Aggrecans ,Enzyme Inhibitors ,Organic Chemicals ,Collagen Type II ,Aged - Abstract
To determine the effect of BAY 12-9566, a matrix metalloproteinase inhibitor, on articular cartilage metabolism in patients with osteoarthritis (OA).Thirty-five patients with OA were randomized to receive oral daily dosing of BAY 12-9566 (25, 100, or 400 mg) or placebo for 3 weeks prior to knee surgery. Cartilage samples were obtained at surgery and examined for markers of proteoglycan aggrecan turnover (846 epitope, a putative synthesis marker, and keratan sulfate epitope content) and type II collagen synthesis (C-propeptide content), cleavage by collagenase (COL 2-3/4C short), denaturation, and content (COL2-3/4m epitope). BAY 12-9566 concentrations were measured by HPLC in serum, synovial fluid, and cartilage.Comparisons between study drug and placebo treatments revealed that at the 100 mg dose there was a significant increase in the 846 epitope (p = 0.012). Total type II collagen content was also higher at this dosage (p = 0.012). Alterations in collagen degradation and synthesis were not detected.BAY 12-9566 at daily doses of 100 mg significantly altered proteoglycan turnover, resulting in a cartilage composition reflected by the content of the 846 epitope that is more characteristic of a young growing individual. The increase in this epitope may signify increased matrix synthesis. The increase in type II collagen content was unexpected, since there was no other evidence for altered collagen turnover. However, increased matrix assembly would also be indicated by this increased content.
- Published
- 2003
18. Final overall survival from a phase 3 trial of nab-paclitaxel versus dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma
- Author
-
Markus F. Renschler, Michael P. Brown, Richard F. Kefford, Michele Del Vecchio, Mingyu Li, Alessandro Testori, Carmen Loquai, Ileana Elias, Ralf Gutzmer, Evan M. Hersh, Andrew Haydon, Shailender Bhatia, Caroline Robert, and Axel Hauschild
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Metastatic melanoma ,business.industry ,medicine.medical_treatment ,Hazard ratio ,Surgery ,Internal medicine ,Overall survival ,Medicine ,Dacarbazine - DTIC ,business ,Chemotherapy naive ,Nab-paclitaxel - Abstract
9045 Background: In a phase 3 trial, nab-paclitaxel significantly improved progression-free survival (PFS) compared with DTIC (4.8 vs 2.5 months; hazard ratio [HR] 0.792; P = 0.044) in chemotherapy...
- Published
- 2014
19. A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status
- Author
-
Evan M. Hersh, Mingyu Li, Axel Hauschild, Michele Del Vecchio, Carmen Loquai, Alessandro Testori, Michael P. Brown, Caroline Robert, Richard F. Kefford, Ileana Elias, and Markus F. Renschler
- Subjects
Oncology ,Cancer Research ,Poor prognosis ,medicine.medical_specialty ,Metastatic melanoma ,business.industry ,Dacarbazine ,Internal medicine ,medicine ,business ,neoplasms ,Chemotherapy naive ,medicine.drug ,Nab-paclitaxel - Abstract
9030 Background: Activating mutations of BRAF V600 can be found in 40%-50% of melanomas and are related to poor prognosis. In a phase 3 trial for the treatment of metastatic melanoma (MM) in chemotherapy-naive patients, nab-paclitaxel (nab-P) vs dacarbazine (DTIC) demonstrated a significant improvement in the primary endpoint of progression-free survival (PFS), assessed by independent radiological review (IRR), and a trend toward prolonged overall survival (OS) at the interim survival analysis. The study also explored the effect of BRAF status on the efficacy parameters. Methods: Chemotherapy-naive patients with stage IV melanoma (M1c stage 65%; elevated LDH 28%) and ECOG performance status 0-1 were randomized to nab-P 150 mg/m2 on days 1, 8, and 15 of a 28-day cycle (n = 264) or DTIC 1000 mg/m2 on day 1 of each 21-day cycle (n = 265) independent of BRAF status. Prespecified subgroup analyses of final PFS and interim OS in subgroups by BRAF status (V600E mutant, wild-type, or unknown) were performed. Results: BRAF mutation status was balanced between the treatment arms, with 36% and 38% of patients with known BRAF mutation status in the nab-P and DTIC arms, respectively. Patient characteristics were also balanced within BRAF subgroups. As shown in the Table, advantage in the nab-P arm vs DTIC arm was observed for both PFS and interim OS regardless of BRAFmutation status. Poststudy BRAF inhibitor treatment was also balanced. Conclusions: In this phase III trial, treatment effect was independent of BRAF mutation status, benefiting all patients who received nab-P vs DTIC. Therefore nab-P should be considered in the armamentarium for all chemotherapy-naive patients with MM. Clinical trial information: NCT00864253. [Table: see text]
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.